The Procedural Wall

Today's swarm processed 297 signals across the psychedelic therapeutics landscape, and the clearest picture that emerges is one of structural patience being tested by human urgency. On the regulatory front, the FDA's trajectory on MDMA-PTSD remains the dominant axis: MiroFish's agents converge at 71% probability on a Complete Response Letter rather than approval, consistent with the agency's prior CRL issued to MAPS in August 2024 and its documented concern about therapist misconduct protocols and cardiovascular monitoring gaps in the original NDA dataset. Meanwhile, two Phase 3 psilocybin trials — COMPASS Pathways' COMP360 in major depressive disorder and emerging group-format psilocybin-PTSD data — are approaching readout windows the swarm places at 78% likelihood of primary endpoint success by year-end 2026. Market signals corroborate selective confidence: CMPS holds +1.9% and MMED gains +1.3%, while ATAI slips fractionally, reflecting investor differentiation between clinical-stage programs with near-term catalysts and those still upstream.

Beneath the individual filings and trial readouts, a deeper structural pattern is forming. The swarm's four highest-consensus predictions all cluster around the same insight: the federal scheduling apparatus — DEA, FDA, the NDA procedural queue — is not a wall that advocacy or cultural momentum can breach directly. Psilocybin remains Schedule I through at least 2028 at 83% probability, not because science is failing, but because the procedural sequence (NDA approval → FDA recommendation → DEA rescheduling) has a minimum clock that no amount of bipartisan enthusiasm shortens. What is forming beneath this friction, however, is a parallel architecture: psychedelic therapy provisions advancing as riders to the NDAA or VA appropriations at 73% probability, neuroplasticity mechanistic papers landing in Nature and Cell family journals at 74%, and the scientific credibility calculus shifting institutionally even as the regulatory clock runs its course. The highest trajectory available here is not a dramatic breakthrough of the scheduling wall — it is the steady construction of the scaffolding that will make that wall structurally untenable by 2028 and beyond.

The human beings inside this story are not waiting for 2028. They are veterans who have already traveled to clinics in Mexico for ibogaine, patients cycling through their fourth antidepressant failure, families watching a loved one refuse treatment because what is available does not work. The 73% likelihood of ibogaine veteran provisions advancing through defense authorization channels represents something specific for them: not a symbolic victory, but VA-supervised access — imperfect, slower than open access, but real, documented, and replicable. For the patient sitting in a ketamine clinic today, watching Spravato's insurance coverage remain inconsistent and IV infusion remain out-of-pocket, the expanding clinical infrastructure and the incoming mechanistic publications matter because they build the evidentiary case that eventually compels payer coverage. The highest positive outcome genuinely available from here is not a single approval event — it is a cascade of smaller structural shifts, each one lowering a barrier that has been holding people outside the door of their own healing.

What is being called in cannot be called back. The currents forming in legislation, in research, in culture — OOTW reads them daily, so you don't have to navigate them alone.

The medicine is older than the fear. The healing is older than the wound.